GlassScriptPhysician profile
Ashvin A Patel
NPI 1730209172
$67,884.45
in general payments reported to CMS, 2019-2025
32 companies · $3,037 in 2025
The $3,037 reported for 2025 was more than what 93% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $8,453 · 2021: $16K · 2022: $5,030 · 2023: $14K · 2024: $7,535 · 2025: $3,037.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Food and Beverage: $9,331 · Travel and Lodging: $118 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,850.00 |
| Food and Beverage | $9,330.51 |
| Travel and Lodging | $117.90 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $31,967.48 | 2021-2025 | |
| Allergan, INC. | $16,981.02 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $6,028.34 | 2020-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $1,811.21 | 2019-2025 | Spravato, Invega Sustenna |
| Alkermes, INC. | $1,317.70 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $1,209.32 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Corium, LLC | $966.97 | 2022-2025 | Azstarys |
| Neurocrine Biosciences, INC. | $876.77 | 2019-2025 | Ingrezza |
| Lundbeck LLC | $839.27 | 2019-2025 | Abilify Asimtufii, Rexulti |
| Vanda Pharmaceuticals INC. | $775.38 | 2019-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $753.16 | 2019-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $573.91 | 2022-2024 | Qelbree, Qelbree |
| Sunovion Pharmaceuticals INC. | $561.92 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $495.89 | 2019-2024 | Jornay Pm |
| Axsome Therapeutics, INC. | $399.23 | 2022-2025 | Auvelity, Sunosi |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $384.58 | 2019-2025 | Wellbutrin, Aplenzin |
| E.R. Squibb & Sons, L.L.C. | $314.56 | 2024-2025 | Cobenfy |
| Neos Therapeutics, LP | $224.37 | 2020-2024 | Adzenys Xr-Odt |
| Tris Pharma INC | $217.63 | 2022-2024 | Dyanavel Xr, Quillivant, Quillichew Er |
| Avanir Pharmaceuticals, INC. | $211.98 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $200.10 | 2025 | Jornay Pm |
| Eisai INC. | $152.16 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $123.23 | 2019-2023 | Uzedy, Austedo Xr |
| Jazz Pharmaceuticals INC. | $112.64 | 2020-2022 | |
| Neuronetics, INC. | $95.03 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $74.67 | 2022-2023 | Belsomra |
| Noven Therapeutics, LLC | $70.66 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $63.34 | 2022-2023 | Quviviq |
| Almatica Pharma LLC | $33.65 | 2021-2024 | Loreev Xr |
| Indivior INC. | $19.66 | 2022 | |
| Shire North American Group INC | $14.39 | 2019 | |
| Adlon Therapeutics L.P. | $14.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashvin Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.